Skip to main content
. 2011 May 2;121(6):2361–2370. doi: 10.1172/JCI45213

Figure 7. TIF1G is sensitive to decitabine in CMML.

Figure 7

(A) TIF1G expression (RQ-PCR) from the monocytes (CD14+) of two CMML patients (1 and 2) after 3 days of culture in the absence or presence of decitabine (dec). Data are the mean ± SD of the values from experiments performed in triplicate. (B) TIF1G expression (RQ-PCR) from the monocytes of one CMML patient before and during treatment with decitabine. Data are the mean ± SD of the values from experiments performed in triplicate. (C) Immunoblotting analysis for TIF1γ in human monocytes from the same patient after 5 cycles of decitabine. Equivalent loading of the lanes was controlled by anti-HSC70 antibody staining. (D) Sequencing of the bisulfite-modified TIF1G promoter sequence from the monocytes of two patients before and after 7 cycles of decitabine (CMML 1 is the same patient as in B).